{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:02:51Z","timestamp":1790863371377,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00277-022-05035-y","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T07:03:06Z","timestamp":1668668586000},"page":"245-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-1599","authenticated-orcid":false,"given":"Tim","family":"Str\u00fc\u00dfmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Duque Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"5035_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492187","volume":"41","author":"A Matzdorff","year":"2018","unstructured":"Matzdorff A et al (2018) Immune thrombocytopenia - current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI. Oncol Res Treat 41:1\u201330","journal-title":"Oncol Res Treat"},{"key":"5035_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J et al (2018) Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 93:921\u2013930","journal-title":"Am J Hematol"},{"key":"5035_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","volume":"146","author":"DM Arnold","year":"2007","unstructured":"Arnold DM et al (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25\u201333","journal-title":"Ann Intern Med"},{"key":"5035_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1084\/jem.20040168","volume":"199","author":"BF Hoyer","year":"2004","unstructured":"Hoyer BF et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice. J Exp Med 199:1577\u20131584","journal-title":"J Exp Med"},{"key":"5035_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754\u2013766","journal-title":"N Engl J Med"},{"key":"5035_CR6","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","volume":"2","author":"C Schuetz","year":"2018","unstructured":"Schuetz C et al (2018) Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv 2:2550\u20132553","journal-title":"Blood Adv"},{"key":"5035_CR7","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1111\/bjh.17565","volume":"194","author":"P Khandelwal","year":"2021","unstructured":"Khandelwal P et al (2021) Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Br J Haematol 194:e84\u2013e89","journal-title":"Br J Haematol"},{"key":"5035_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/bloodadvances.2019001215","volume":"4","author":"Y Migdady","year":"2020","unstructured":"Migdady Y et al (2020) Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Adv 4:815\u2013818","journal-title":"Blood Adv"},{"key":"5035_CR9","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","volume":"106","author":"E Crickx","year":"2021","unstructured":"Crickx E et al (2021) Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. Haematologica 106:3198\u20133201","journal-title":"Haematologica"},{"key":"5035_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","volume":"100","author":"A Jain","year":"2021","unstructured":"Jain A, Gupta DK (2021) Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol 100:1351\u20131353","journal-title":"Ann Hematol"},{"key":"5035_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/bjh.17655","volume":"194","author":"MJ Rieger","year":"2021","unstructured":"Rieger MJ et al (2021) Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. Br J Haematol 194:931\u2013934","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05035-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05035-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T03:04:25Z","timestamp":1672715065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05035-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5035"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05035-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}